Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
681152-60-7
|
| gptkbp:clinicalTrialPhase |
Phase III (failed)
|
| gptkbp:developedBy |
gptkb:Alzheimer's_disease
|
| gptkbp:developer |
gptkb:Axovant_Sciences
|
| gptkbp:hasMolecularFormula |
C23H28F3N3O
|
| gptkbp:IUPACName |
3-(2,2,2-trifluoro-1-methyl-1H-indol-3-yl)-N-(piperidin-1-yl)propanamide
|
| gptkbp:mechanismOfAction |
5-HT6 receptor antagonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:synonym |
SB-742457
|
| gptkbp:bfsParent |
gptkb:Axovant_Sciences
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
intepirdine
|